NeurogesX Provides Update on Qutenza(R) (Capsaicin) 8% Patch for New Indication to Treat HIV-PN Following FDA Advisory Committee Review
February 09, 2012 17:30 ET
|
NeurogesX
SAN MATEO, Calif., Feb. 9, 2012 (GLOBE NEWSWIRE) -- NeurogesX (Nasdaq:NGSX), a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, pain...
NeurogesX' Stock Trading Halted Today
February 09, 2012 07:01 ET
|
NeurogesX
SAN MATEO, Calif., Feb. 9, 2012 (GLOBE NEWSWIRE) -- NeurogesX Inc., a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, pain management,...
NeurogesX Grants Equity Awards Under Its 2011 Inducement Stock Plan
February 03, 2012 16:15 ET
|
NeurogesX
SAN MATEO, Calif., Feb. 3, 2012 (GLOBE NEWSWIRE) -- NeurogesX, Inc. (Nasdaq:NGSX), a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, pain...
NeurogesX, Inc. Announces $3.0 Million Private Placement
February 01, 2012 08:45 ET
|
NeurogesX
SAN MATEO, Calif., Feb. 1, 2012 (GLOBE NEWSWIRE) -- NeurogesX, Inc. (Nasdaq:NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today...
NeurogesX Appoints Ronald Martell President and Chief Executive Officer
January 03, 2012 10:00 ET
|
NeurogesX
SAN MATEO, Calif., Jan. 3, 2012 (GLOBE NEWSWIRE) -- NeurogesX, Inc. (Nasdaq:NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today...
NeurogesX Confirms FDA Advisory Committee to Review sNDA for Qutenza(R) (capsaicin) 8% Patch for HIV-Associated Peripheral Neuropathy (HIV-PN)
December 15, 2011 14:40 ET
|
NeurogesX
SAN MATEO, Calif., Dec. 15, 2011 (GLOBE NEWSWIRE) -- NeurogesX, Inc. (Nasdaq:NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today...
NeurogesX Receives FDA Acceptance for Review of sNDA for Qutenza(R) (capsaicin) 8% Patch for HIV-Associated Peripheral Neuropathy (HIV-PN)
November 14, 2011 16:10 ET
|
NeurogesX
SAN MATEO, Calif., Nov. 14, 2011 (GLOBE NEWSWIRE) -- NeurogesX, Inc. (Nasdaq:NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today...
NeurogesX to Present at Lazard Capital Markets 8th Annual Healthcare Conference
November 09, 2011 16:28 ET
|
NeurogesX
SAN MATEO, Calif., Nov. 9, 2011 (GLOBE NEWSWIRE) -- NeurogesX, Inc. (Nasdaq:NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced...
NeurogesX to Hold Conference Call Today at 8:30 a.m. ET to Discuss NGX-1998 Phase 2 Clinical Study Results
November 08, 2011 07:25 ET
|
NeurogesX
SAN MATEO, Calif., Nov. 8, 2011 (GLOBE NEWSWIRE) -- NeurogesX, Inc. (Nasdaq:NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced it...
NeurogesX Reports Positive Phase 2 Results for NGX-1998 for Treatment of Postherpetic Neuralgia
November 08, 2011 07:20 ET
|
NeurogesX
Study Results Support 5 Minute Application of Topical Liquid Capsaicin Formulation
Conference Call Today at 8:30am (ET)
SAN MATEO, Calif., Nov. 8, 2011 (GLOBE NEWSWIRE) -- NeurogesX, Inc....